The problems span some doses of branded and generic Adderall and are being caused by issues at one manufacturing facility. The disruptions could last into the fall, the company told Bloomberg News.
The problems “are associated with packaging capacity constraints,” said Yonatan Beker, a Teva spokesperson. The company declined to provide more information about exactly what the packaging issues are.
Adderall is ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.
